Vipul Lakhani, MD
Ophthalmology · Toms River, NJNPI 1982689303
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $8,506 of the $9,825 with a category attached, or 86.6%. 36 manufacturers reported payments, led by Alcon at 38.3% of the total. Among ophthalmology clinicians in NJ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 442 payments — averaging $22.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$4K
- AbbVie$2K
- Sun Pharmaceutical Industries Inc.$876
- Amgen$506
- Bausch & Lomb Americas Inc.$421
- Oyster Point Pharma, Inc.$419
- plus $2K from 30 others
Across 1 payment — averaging $400.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ivantis, Inc$400
What the payments were for
- Travel & lodging$1,21012%
- Food & beverage$8,50687%
- Education$911%
- Gifts$170%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 119 | $3,759 |
| AbbVie(2 entities) | 83 | $1,623 |
| Sun Pharmaceutical Industries Inc. | 48 | $876 |
| Amgen(2 entities) | 32 | $506 |
| Bausch & Lomb Americas Inc. | 16 | $421 |
| Oyster Point Pharma, Inc. | 20 | $419 |
| Tarsus Pharmaceuticals, Inc. | 22 | $368 |
| AstraZeneca | 12 | $176 |
| Biotissue Holdings Inc. | 8 | $154 |
| Ocular Therapeutix, Inc. | 10 | $151 |
| Rxsight Inc | 2 | $135 |
| Sight Sciences, Inc. | 8 | $132 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 8 | $110 |
| Kala Pharmaceuticals, Inc. | 6 | $103 |
| Dompe US, Inc. | 5 | $93 |
| NEW World Medical,inc. | 4 | $82 |
| Ivantis, Inc | 4 | $80 |
| Carl Zeiss Meditec, Inc. | 1 | $65 |
| Johnson & Johnson Surgical Vision, Inc. | 3 | $62 |
| Novartis | 4 | $59 |
| Aerie Pharmaceuticals, Inc. | 4 | $57 |
| Harrow Eye, LLC | 2 | $44 |
| Mallinckrodt Hospital Products Inc. | 3 | $42 |
| Astellas Pharma US Inc | 2 | $34 |
| Thea Pharma Inc. | 2 | $34 |
| Rayner Intraocular Lenses Limited | 2 | $34 |
| Omeros Corporation | 2 | $31 |
| Merz Pharmaceuticals, LLC | 2 | $28 |
| Glaukos Corporation | 1 | $24 |
| Johnson & Johnson | 1 | $23 |
| UCB, Inc. | 1 | $20 |
| Spark Therapeutics, Inc. | 1 | $18 |
| Carl Zeiss Meditec AG | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Argenx US, Inc. | 1 | $16 |
| Eyevance Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof$683
- MIEBO$235
- XIIDRA$235
- Rocklatan$125
- Rhopressa$125
- TEPEZZA$125
- TRYPTYR$125
- XEN GLAUCOMA TREATMENT SYSTEM$123
- Clareon$119
- CEQUA$114
- RXSIGHT INJECTOR HANDPIECE$113
- RXSIGHT CONTACT LENS$113
- RXSIGHT INJECTOR CARTRIDGE$113
- LIGHT ADJUSTABLE LENS (LAL)$113
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$113
- LUMIGAN$112
- COMBIGAN$112
- TYRVAYA$111
How this compares
$9,825 in reported general payments places this provider in the 90th percentile of 583 ophthalmology providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 316 | $139,438 |
| XdemvyLotilaner | 59 | $107,373 |
| RestasisCyclosporine | 86 | $97,356 |
| XiidraLifitegrast | 78 | $85,857 |
| RocklatanNetarsudil Mesylat/Latanoprost | 181 | $82,540 |
| RhopressaNetarsudil Mesylate | 161 | $64,488 |
| VyzultaLatanoprostene Bunod | 123 | $42,710 |
| BesivanceBesifloxacin Hcl | 189 | $42,100 |
| Difluprednate | 302 | $27,990 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 114 | $26,112 |
| CequaCyclosporine | 21 | $21,837 |
| ProlensaBromfenac Sodium | 57 | $21,009 |
| Cyclosporine | 23 | $19,680 |
| Bromfenac Sodium | 103 | $17,941 |
| MieboPerfluorohexyloctane/Pf | 17 | $16,662 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis, Alphagan P, Combigan | $1,623 | $257,210479 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $57 | $147,028342 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $421 | $145,229218 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $368 | $107,37359 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCBesivance, Prolensa | $110 | $63,109246 claims |
| AlconSimbrinza | $3,759 | $26,112114 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $876 | $21,83721 claims |
| Thea Pharma Inc.Iyuzeh | $34 | $13,78023 claims |
| Harrow Eye, LLCVevye | $44 | $10,78315 claims |
| Oyster Point Pharma, Inc.Tyrvaya | $419 | $9,54115 claims |
| NovartisIlevro | $59 | $4,11211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 ophthalmology providers in New Jersey.
Other ophthalmology in Toms River
- Jai ParekhWoodland Park$2M
- Sharad MansukaniMoorestown$744K
- Ravi PatelEatontown$729K
- Cynthia MatossianPennington$655K
- Eric MannDover$604K
- Brett BieloryRutherford$477K
- Albert KhouriNewark$428K
- Robert FechtnerNewark$324K
- Rajen DesaiFreehold$311K
- Douglas GraysonIselin$158K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.